Xiaojie (Zoe) Zhang
@zoezhang.bsky.social
Breast Medical Oncologist at UCSD |Former UCSD Hemonc fellow | Uchicago & DukeMed Alum
Passionate about breast cancer care and research
Passionate about breast cancer care and research
Excited to present "AI for precision oncology: Real-world analysis of a CDK4/6 inhibitor model" with @akshatsinghal.bsky.social at #ACSSpring2025 this weekend! Love sharing our work with different crowds!
March 19, 2025 at 9:37 PM
Excited to present "AI for precision oncology: Real-world analysis of a CDK4/6 inhibitor model" with @akshatsinghal.bsky.social at #ACSSpring2025 this weekend! Love sharing our work with different crowds!
18/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
Beyond SERDs/SERMs…novel endocrine therapies targeting other mechanisms in pipeline:
Proteolysis targeting chimeras (PROTACs), selective ER covalent antagonists, complete ER antagonists just to name a few!🤯
Beyond SERDs/SERMs…novel endocrine therapies targeting other mechanisms in pipeline:
Proteolysis targeting chimeras (PROTACs), selective ER covalent antagonists, complete ER antagonists just to name a few!🤯
January 15, 2025 at 1:50 AM
18/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
Beyond SERDs/SERMs…novel endocrine therapies targeting other mechanisms in pipeline:
Proteolysis targeting chimeras (PROTACs), selective ER covalent antagonists, complete ER antagonists just to name a few!🤯
Beyond SERDs/SERMs…novel endocrine therapies targeting other mechanisms in pipeline:
Proteolysis targeting chimeras (PROTACs), selective ER covalent antagonists, complete ER antagonists just to name a few!🤯
17/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
Beyond EMBER-3, novel combinations with SERDs and SERMs also being evaluated with CDK4/6i
Beyond EMBER-3, novel combinations with SERDs and SERMs also being evaluated with CDK4/6i
January 15, 2025 at 1:48 AM
17/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
Beyond EMBER-3, novel combinations with SERDs and SERMs also being evaluated with CDK4/6i
Beyond EMBER-3, novel combinations with SERDs and SERMs also being evaluated with CDK4/6i
17/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
➡️Multiple novel SERDS studied in HR+/HER2- ABC
👍Elacestrant currently remains the only FDA approved option
🚧Novel SERDs w/ unique AEs from fulvestrant
⚡This is a rapidly changing landscape!
➡️Multiple novel SERDS studied in HR+/HER2- ABC
👍Elacestrant currently remains the only FDA approved option
🚧Novel SERDs w/ unique AEs from fulvestrant
⚡This is a rapidly changing landscape!
January 15, 2025 at 1:46 AM
17/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
➡️Multiple novel SERDS studied in HR+/HER2- ABC
👍Elacestrant currently remains the only FDA approved option
🚧Novel SERDs w/ unique AEs from fulvestrant
⚡This is a rapidly changing landscape!
➡️Multiple novel SERDS studied in HR+/HER2- ABC
👍Elacestrant currently remains the only FDA approved option
🚧Novel SERDs w/ unique AEs from fulvestrant
⚡This is a rapidly changing landscape!
15/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
👩⚕️Mini Tutorial 6👩⚕️
Imlunestrant: favorable safety profile vs SoC. Dc rate: 4%
Imlun+abema: diarrhea=most common AE, all grade: 86%, grade≥3: 8%. Dc rate: 6%
No 👁️or 💙AE signals like in other oral SERDS (i.e. photopsia, bradycardia in camizestrant)
👩⚕️Mini Tutorial 6👩⚕️
Imlunestrant: favorable safety profile vs SoC. Dc rate: 4%
Imlun+abema: diarrhea=most common AE, all grade: 86%, grade≥3: 8%. Dc rate: 6%
No 👁️or 💙AE signals like in other oral SERDS (i.e. photopsia, bradycardia in camizestrant)
January 15, 2025 at 1:42 AM
15/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
👩⚕️Mini Tutorial 6👩⚕️
Imlunestrant: favorable safety profile vs SoC. Dc rate: 4%
Imlun+abema: diarrhea=most common AE, all grade: 86%, grade≥3: 8%. Dc rate: 6%
No 👁️or 💙AE signals like in other oral SERDS (i.e. photopsia, bradycardia in camizestrant)
👩⚕️Mini Tutorial 6👩⚕️
Imlunestrant: favorable safety profile vs SoC. Dc rate: 4%
Imlun+abema: diarrhea=most common AE, all grade: 86%, grade≥3: 8%. Dc rate: 6%
No 👁️or 💙AE signals like in other oral SERDS (i.e. photopsia, bradycardia in camizestrant)
14/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
👩⚕️Mini Tutorial 5👩⚕️
🔑Findings:
PFS ESR1m: 5.5 (Imlun) vs 3.8 mon (SoC). HR= 0.62, p<0.001
PFS all: 9.4 (Imlun+abema) vs 5.5 mon (imlun). HR=0.57, p<0.001
Benefit of imlun+abema in key subgroups: ESR1m, PIK3CAm, visceral disease, prior CDK4/6i
👩⚕️Mini Tutorial 5👩⚕️
🔑Findings:
PFS ESR1m: 5.5 (Imlun) vs 3.8 mon (SoC). HR= 0.62, p<0.001
PFS all: 9.4 (Imlun+abema) vs 5.5 mon (imlun). HR=0.57, p<0.001
Benefit of imlun+abema in key subgroups: ESR1m, PIK3CAm, visceral disease, prior CDK4/6i
January 15, 2025 at 1:40 AM
14/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
👩⚕️Mini Tutorial 5👩⚕️
🔑Findings:
PFS ESR1m: 5.5 (Imlun) vs 3.8 mon (SoC). HR= 0.62, p<0.001
PFS all: 9.4 (Imlun+abema) vs 5.5 mon (imlun). HR=0.57, p<0.001
Benefit of imlun+abema in key subgroups: ESR1m, PIK3CAm, visceral disease, prior CDK4/6i
👩⚕️Mini Tutorial 5👩⚕️
🔑Findings:
PFS ESR1m: 5.5 (Imlun) vs 3.8 mon (SoC). HR= 0.62, p<0.001
PFS all: 9.4 (Imlun+abema) vs 5.5 mon (imlun). HR=0.57, p<0.001
Benefit of imlun+abema in key subgroups: ESR1m, PIK3CAm, visceral disease, prior CDK4/6i
13/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
👩⚕️Mini Tutorial 4👩⚕️
Novel, oral SERDs in development w/ ⬆️efficacy ⬇️toxicities
👉💡imlunestrant, studied in the EMBER-3 trial presented at #SABCS24
🔑Pt features:
~37% with ESR1m, ~40% with PIK3CAm, >50% visceral disease
👉1/3 adj ET, 2/3 prior CDK4/6i
👩⚕️Mini Tutorial 4👩⚕️
Novel, oral SERDs in development w/ ⬆️efficacy ⬇️toxicities
👉💡imlunestrant, studied in the EMBER-3 trial presented at #SABCS24
🔑Pt features:
~37% with ESR1m, ~40% with PIK3CAm, >50% visceral disease
👉1/3 adj ET, 2/3 prior CDK4/6i
January 15, 2025 at 1:38 AM
13/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
👩⚕️Mini Tutorial 4👩⚕️
Novel, oral SERDs in development w/ ⬆️efficacy ⬇️toxicities
👉💡imlunestrant, studied in the EMBER-3 trial presented at #SABCS24
🔑Pt features:
~37% with ESR1m, ~40% with PIK3CAm, >50% visceral disease
👉1/3 adj ET, 2/3 prior CDK4/6i
👩⚕️Mini Tutorial 4👩⚕️
Novel, oral SERDs in development w/ ⬆️efficacy ⬇️toxicities
👉💡imlunestrant, studied in the EMBER-3 trial presented at #SABCS24
🔑Pt features:
~37% with ESR1m, ~40% with PIK3CAm, >50% visceral disease
👉1/3 adj ET, 2/3 prior CDK4/6i
12/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
2023, FDA approved elacestrant based on the EMERALD trial
Pts: prior 1-2L ET, ≤1 chemo for ABC: R 1:1 ➡️elacestrant vs SoC
➡️
PFS all: HR = 0.70; p = .002
PFS ESR1m: HR = 0.55; p = .0005
Benefit in key subgroups: PIK3CA mut, ESR1 mut, and TP53 mut
2023, FDA approved elacestrant based on the EMERALD trial
Pts: prior 1-2L ET, ≤1 chemo for ABC: R 1:1 ➡️elacestrant vs SoC
➡️
PFS all: HR = 0.70; p = .002
PFS ESR1m: HR = 0.55; p = .0005
Benefit in key subgroups: PIK3CA mut, ESR1 mut, and TP53 mut
January 15, 2025 at 1:36 AM
12/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
2023, FDA approved elacestrant based on the EMERALD trial
Pts: prior 1-2L ET, ≤1 chemo for ABC: R 1:1 ➡️elacestrant vs SoC
➡️
PFS all: HR = 0.70; p = .002
PFS ESR1m: HR = 0.55; p = .0005
Benefit in key subgroups: PIK3CA mut, ESR1 mut, and TP53 mut
2023, FDA approved elacestrant based on the EMERALD trial
Pts: prior 1-2L ET, ≤1 chemo for ABC: R 1:1 ➡️elacestrant vs SoC
➡️
PFS all: HR = 0.70; p = .002
PFS ESR1m: HR = 0.55; p = .0005
Benefit in key subgroups: PIK3CA mut, ESR1 mut, and TP53 mut
10/20 #TumorBoardTuesday
👩⚕️Mini Tutorial 1👩⚕️
Therapy options after progression on 1L ET+CDK4/6i are biomarker driven.
@dr-rshatsky.bsky.social
👩⚕️Mini Tutorial 1👩⚕️
Therapy options after progression on 1L ET+CDK4/6i are biomarker driven.
@dr-rshatsky.bsky.social
January 15, 2025 at 1:31 AM
10/20 #TumorBoardTuesday
👩⚕️Mini Tutorial 1👩⚕️
Therapy options after progression on 1L ET+CDK4/6i are biomarker driven.
@dr-rshatsky.bsky.social
👩⚕️Mini Tutorial 1👩⚕️
Therapy options after progression on 1L ET+CDK4/6i are biomarker driven.
@dr-rshatsky.bsky.social
8/20 #TumorBoardTuesday
⚖️ efficacy with safety…
Inavo arm: ↑AEs vs control
All-grade hyperglycemia: 58.6%; grade 3 or 4: 5.6%
All-grade stomatitis: 51.2%; grade 3 or 4: 5.6%
All-grade diarrhea: 48.1%; grade 3 or 4: 3.7%
1° ppx for above was not offered in the trial
@dr-rshatsky.bsky.social
⚖️ efficacy with safety…
Inavo arm: ↑AEs vs control
All-grade hyperglycemia: 58.6%; grade 3 or 4: 5.6%
All-grade stomatitis: 51.2%; grade 3 or 4: 5.6%
All-grade diarrhea: 48.1%; grade 3 or 4: 3.7%
1° ppx for above was not offered in the trial
@dr-rshatsky.bsky.social
January 15, 2025 at 1:24 AM
8/20 #TumorBoardTuesday
⚖️ efficacy with safety…
Inavo arm: ↑AEs vs control
All-grade hyperglycemia: 58.6%; grade 3 or 4: 5.6%
All-grade stomatitis: 51.2%; grade 3 or 4: 5.6%
All-grade diarrhea: 48.1%; grade 3 or 4: 3.7%
1° ppx for above was not offered in the trial
@dr-rshatsky.bsky.social
⚖️ efficacy with safety…
Inavo arm: ↑AEs vs control
All-grade hyperglycemia: 58.6%; grade 3 or 4: 5.6%
All-grade stomatitis: 51.2%; grade 3 or 4: 5.6%
All-grade diarrhea: 48.1%; grade 3 or 4: 3.7%
1° ppx for above was not offered in the trial
@dr-rshatsky.bsky.social
6/20 #TumorBoardTuesday
👩⚕️Mini Tutorial 3👩⚕️
Pts R 1:1 to Inavo vs placebo +palbo+fulv
🔑findings:
Median f/u: 21.3 mon
Median PFS: 15.0 mon(Inavo) vs 7.3 mon (control) (HR 0.43; p<0.0001)
ORR: 58.4% (Inavo) vs 25% (control)
Consistent benefit across key subgroups
@dr-rshatsky.bsky.social
👩⚕️Mini Tutorial 3👩⚕️
Pts R 1:1 to Inavo vs placebo +palbo+fulv
🔑findings:
Median f/u: 21.3 mon
Median PFS: 15.0 mon(Inavo) vs 7.3 mon (control) (HR 0.43; p<0.0001)
ORR: 58.4% (Inavo) vs 25% (control)
Consistent benefit across key subgroups
@dr-rshatsky.bsky.social
January 15, 2025 at 1:20 AM
6/20 #TumorBoardTuesday
👩⚕️Mini Tutorial 3👩⚕️
Pts R 1:1 to Inavo vs placebo +palbo+fulv
🔑findings:
Median f/u: 21.3 mon
Median PFS: 15.0 mon(Inavo) vs 7.3 mon (control) (HR 0.43; p<0.0001)
ORR: 58.4% (Inavo) vs 25% (control)
Consistent benefit across key subgroups
@dr-rshatsky.bsky.social
👩⚕️Mini Tutorial 3👩⚕️
Pts R 1:1 to Inavo vs placebo +palbo+fulv
🔑findings:
Median f/u: 21.3 mon
Median PFS: 15.0 mon(Inavo) vs 7.3 mon (control) (HR 0.43; p<0.0001)
ORR: 58.4% (Inavo) vs 25% (control)
Consistent benefit across key subgroups
@dr-rshatsky.bsky.social
4/20 #TumorBoardTuesday
👩⚕️Mini Tutorial 1👩⚕️
Oct 2024, FDA approved inavolisib, palbociclib, and fulvestrant in endocrine resistant HR+/HER2- advanced breast cancer, based on the phase 3, INAVO120 study
@dr-rshatsky.bsky.social
👩⚕️Mini Tutorial 1👩⚕️
Oct 2024, FDA approved inavolisib, palbociclib, and fulvestrant in endocrine resistant HR+/HER2- advanced breast cancer, based on the phase 3, INAVO120 study
@dr-rshatsky.bsky.social
January 15, 2025 at 1:15 AM
4/20 #TumorBoardTuesday
👩⚕️Mini Tutorial 1👩⚕️
Oct 2024, FDA approved inavolisib, palbociclib, and fulvestrant in endocrine resistant HR+/HER2- advanced breast cancer, based on the phase 3, INAVO120 study
@dr-rshatsky.bsky.social
👩⚕️Mini Tutorial 1👩⚕️
Oct 2024, FDA approved inavolisib, palbociclib, and fulvestrant in endocrine resistant HR+/HER2- advanced breast cancer, based on the phase 3, INAVO120 study
@dr-rshatsky.bsky.social